| # | Drug | Count |
|---|---|---|
| 0 | ADALIMUMAB | 43 |
| 1 | BEVACIZUMAB | 41 |
| 2 | INFLIXIMAB | 33 |
| 3 | RITUXIMAB | 33 |
| 4 | METHOTREXATE SODIUM | 30 |
| 5 | PREDNISOLONE | 29 |
| 6 | PREDNISOLONE ORAL | 29 |
| 7 | PREDNISOLONE ORAL SOLUTION | 29 |
| 8 | ADALIMUMAB-ADAZ | 27 |
| 9 | METHOTREXATE | 26 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | TELMISARTAN AND AMLODIPINE | 1 | 0.0100 |
| 1 | BEVACIZUMAB-ADCD | 2 | 0.0099 |
| 2 | PAPAVERINE HYDROCHLORIDE | 1 | 0.0098 |
| 3 | HYDROXYPROGESTERONE CAPROATE | 1 | 0.0075 |
| 4 | QUAZEPAM | 1 | 0.0033 |
| 5 | DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM | 1 | 0.0027 |
| 6 | PALIFERMIN | 1 | 0.0026 |
| 7 | FOSNETUPITANT AND PALONOSETRON | 3 | 0.0025 |
| 8 | NETUPITANT AND PALONOSETRON | 3 | 0.0025 |
| 9 | TRABECTEDIN | 5 | 0.0021 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Mucocutaneous Epithelial Cell Growth Factor [EPC] | 1 | 0.0026 |
| 1 | CD38-directed Cytolytic Antibody [EPC] | 9 | 0.0015 |
| 2 | CD19-directed Cytolytic Antibody [EPC] | 1 | 0.0012 |
| 3 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 1 | 0.0007 |
| 4 | Guanylate Cyclase-C Agonist [EPC] | 1 | 0.0005 |
| 5 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 39 | 0.0004 |
| 6 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 8 | 0.0004 |
| 7 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 3 | 0.0003 |
| 8 | Epidermal Growth Factor Receptor Antagonist [EPC] | 16 | 0.0003 |
| 9 | Chloride Channel Activator [EPC] | 3 | 0.0003 |